Literature DB >> 21037966

Anti-GD2 Strategy in the Treatment of Neuroblastoma.

Richard K Yang, Paul M Sondel.   

Abstract

The prognosis for advanced neuroblastoma remains poor with high risk of recurrence after consolidation. Therapies based on monoclonal antibodies that specifically target disialoganglioside GD2 on tumor cells are improving treatment results for high-risk neuroblastoma. This article reviews the use of anti-GD2 antibodies either as monotherapy or as part of a larger and more complex treatment approach for advanced neuroblastoma. We review how anti-GD2 antibodies can be combined with other treatments or strategies to enhance their clinical effects. Tumor resistance and other problems that decrease the efficacy of anti-GD2 antibodies are discussed. Future developments in the area of anti-GD2 immunotherapies for neuroblastoma are also addressed.

Entities:  

Year:  2010        PMID： 21037966      PMCID： PMC2964668          DOI： 10.1358/dof.2010.035.08.1513490

Source DB:  PubMed          Journal:  Drugs Future        ISSN： 0377-8282            Impact factor:   0.148


  96 in total

Review 1.  Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant disease.

Authors:  J A Hank; M R Albertini; P M Sondel
Journal:  Cancer Chemother Biol Response Modif       Date:  1999

2.  Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

Authors:  Suzanne Shusterman; Wendy B London; Stephen D Gillies; Jacquelyn A Hank; Stephan D Voss; Robert C Seeger; C Patrick Reynolds; Jennifer Kimball; Mark R Albertini; Barrett Wagner; Jacek Gan; Jens Eickhoff; Kenneth B DeSantes; Susan L Cohn; Toby Hecht; Brian Gadbaw; Ralph A Reisfeld; John M Maris; Paul M Sondel
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

3.  Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.

Authors:  Lisa Marie Serrano; Timothy Pfeiffer; Simon Olivares; Tontanai Numbenjapon; Jennifer Bennitt; Daniel Kim; David Smith; George McNamara; Zaid Al-Kadhimi; Joseph Rosenthal; Stephen J Forman; Michael C Jensen; Laurence J N Cooper
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

4.  Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18).

Authors:  V Vetvicka; B P Thornton; T J Wieman; G D Ross
Journal:  J Immunol       Date:  1997-07-15       Impact factor: 5.422

Review 5.  Idiotypic antibody immunotherapy of cancer.

Authors:  M B Chatterjee; K A Foon; H Köhler
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

6.  Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.

Authors:  Thorsten Simon; Barbara Hero; Andreas Faldum; Rupert Handgretinger; Martin Schrappe; Dietrich Niethammer; Frank Berthold
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

7.  Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.

Authors:  Asahi Ito; Takashi Ishida; Hiroki Yano; Atsushi Inagaki; Susumu Suzuki; Fumihiko Sato; Hisashi Takino; Fumiko Mori; Masaki Ri; Shigeru Kusumoto; Hirokazu Komatsu; Shinsuke Iida; Hiroshi Inagaki; Ryuzo Ueda
Journal:  Cancer Immunol Immunother       Date:  2008-12-02       Impact factor: 6.968

8.  Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells.

Authors:  E Barker; B M Mueller; R Handgretinger; M Herter; A L Yu; R A Reisfeld
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

9.  Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord.

Authors:  L Svennerholm; K Boström; P Fredman; B Jungbjer; A Lekman; J E Månsson; B M Rynmark
Journal:  Biochim Biophys Acta       Date:  1994-09-15

10.  Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.

Authors:  N K Cheung; E I Walter; W H Smith-Mensah; W D Ratnoff; M L Tykocinski; M E Medof
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808
View more
  30 in total

Review 1.  New aspects of neuroblastoma treatment: ASPHO 2011 symposium review.

Authors:  Peter E Zage; Chrystal U Louis; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2012-02-29       Impact factor: 3.167

Review 2.  Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.

Authors:  Julie Voeller; Paul M Sondel
Journal:  J Pediatr Hematol Oncol       Date:  2019-04       Impact factor: 1.289

3.  Ganglioside GD3 Enhances Invasiveness of Gliomas by Forming a Complex with Platelet-derived Growth Factor Receptor α and Yes Kinase.

Authors:  Yuki Ohkawa; Hiroyuki Momota; Akira Kato; Noboru Hashimoto; Yusuke Tsuda; Norihiro Kotani; Koichi Honke; Akio Suzumura; Keiko Furukawa; Yuhsuke Ohmi; Atsushi Natsume; Toshihiko Wakabayashi; Koichi Furukawa
Journal:  J Biol Chem       Date:  2015-05-04       Impact factor: 5.157

4.  Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.

Authors:  Nikolai Siebert; Christin Eger; Diana Seidel; Madlen Jüttner; Maxi Zumpe; Danilo Wegner; Silke Kietz; Karoline Ehlert; Gareth J Veal; Werner Siegmund; Michael Weiss; Hans Loibner; Ruth Ladenstein; Holger N Lode
Journal:  MAbs       Date:  2016-01-19       Impact factor: 5.857

Review 5.  Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.

Authors:  L G Durrant; P Noble; I Spendlove
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

6.  Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.

Authors:  Nikolai Siebert; Christian Jensen; Sascha Troschke-Meurer; Maxi Zumpe; Madlen Jüttner; Karoline Ehlert; Silke Kietz; Ina Müller; Holger N Lode
Journal:  Oncoimmunology       Date:  2016-09-26       Impact factor: 8.110

7.  Positron Emission Tomography Detects In Vivo Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma.

Authors:  Elizabeth R Butch; Paul E Mead; Victor Amador Diaz; Heather Tillman; Elizabeth Stewart; Jitendra K Mishra; Jieun Kim; Armita Bahrami; Jason L J Dearling; Alan B Packard; Shana V Stoddard; Amy L Vāvere; Yuanyuan Han; Barry L Shulkin; Scott E Snyder
Journal:  Cancer Res       Date:  2019-04-23       Impact factor: 12.701

8.  Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA.

Authors:  Gopalan Soman; Xiaoyi Yang; Hengguang Jiang; Steve Giardina; Gautam Mitra
Journal:  J Immunol Methods       Date:  2011-08-26       Impact factor: 2.303

9.  Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2.

Authors:  Richard K Yang; Igor B Kuznetsov; Javed Khan; Paul M Sondel; Erik A Ranheim; Jun S Wei; Sivasish Sindiri; Berkley E Gryder; Vineela Gangalapudi; Young K Song; Viharkumar Patel; Jacquelyn A Hank; Cindy Zuleger; Amy K Erbe; Zachary S Morris; Renae Quale; KyungMann Kim; Mark R Albertini
Journal:  Clin Cancer Res       Date:  2020-03-09       Impact factor: 12.531

10.  Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.

Authors:  Ruth Ladenstein; Silke Weixler; Bianca Baykan; Matthias Bleeke; Renate Kunert; Dietmar Katinger; Ingrid Pribill; Petra Glander; Steffen Bauer; Vito Pistoia; Jean Michon; Alberto Garaventa; Holger N Lode
Journal:  MAbs       Date:  2013-05-31       Impact factor: 5.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.